Table 3. Dose-response analysis regarding MRA use and mortality among PA patients.

	Time varying number at mortality or censer-points	Incidence rate (per 1,000 person-years)	Adjusted HR (95%CI )	P
Daily dose of MRA (expressed as DDD/ Dose)*
<0.17 (12.5 mg)	358	22.67	1.52 (1.18–1.96)	0.001
0.17–0.66 (12.5–50 mg)	196	19.40	1 (ref.)
>0.66 (50 mg)	59	17.47	1.57 (1.01–2.44)	0.044

Abbreviations: CI, confidence interval; DDD, defined daily dose; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; PA, primary aldosteronism.

^*The DDD of MRA was calculated form 30 days to 365 days before mortality or the end of the study.